Weather Alert: Temple Health remains open, though some appointments or services may be adjusted. Patients will be contacted directly if their visit is affected. Please check TempleHealth.org for updates and monitor myTempleHealth for changes to scheduled appointments.

800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

A Study to Evaluate XEN1101 As Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures (X-ACKT)

view all Clinical Trials

Overview

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primary generalized tonic-clonic seizures (PGTCS).

Clinical Trial Information

Protocol

NCT05614063 IRB#: 31589

Phase

3

Condition(s)

Seizures

Investigator

Mercedes P. Jacobson, MD, Valeriya Poukas, MD and Avani A. Shah, MD

Coordinator

Kathleen Hatala, RN, BSN
215-707-4171

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-4171 or email [email protected].

Full Title

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 As Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures